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Abstract
Chemotherapy constitutes the standard modality of treatment for localized head and neck squamous cell carcinomas
(HNSCC). However, many patients fail to respond and relapse after this treatments due to the acquisition of chemo-
resistance. Therefore, there is an urgent need to develop novel drugs that could reverse the resistant phenotype. Curcumin,
the constituent of the spice turmeric has been shown to have anti-inflammatory, anti-oxidant and anti-proliferative
properties in several tumor types. However, use of curcumin has been limited due to its poor bio-absorption. Recently, a
novel class of curcumin analogs, based on diarylidenylpiperidones (DAP), has been developed by incorporating a
piperidone link to the beta-diketone structure and fluoro substitutions on the phenyl groups. In this study, we evaluated the
effectiveness of H-4073, a parafluorinated variant of DAP, using both in vitro and in vivo head and neck cancer models. Our
results demonstrate that H-4073 is a potent anti-tumor agent and it significantly inhibited cell proliferation in all the HNSCC
cell lines tested in a dose-dependent manner. In addition, pretreatment of cisplatin-resistant HNSCC cell lines with H-4073
significantly reversed the chemo-resistance as observed by cell viability assay (MTT), apoptosis assay (Annexin V binding)
and cleaved caspase-3 (Western blot). H-4073 mediated its anti-tumor effects by inhibiting JAK/STAT3, FAK, Akt and VEGF
signaling pathways that play important roles in cell proliferation, migration, survival and angiogenesis. In the SCID mouse
xenograft model, H-4073 significantly enhanced the anti-tumor and anti-angiogenesis effects of cisplatin, with no added
systemic toxicity. Interestingly, H-4073 inhibited tumor angiogenesis by blocking VEGF production by tumor cells as well as
directly inhibiting endothelial cell function. Taken together, our results suggest that H-4073 is a potent anti-tumor agent
and it can be used to overcome chemotherapy resistance in HNSCC.
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Introduction
Head and neck squamous cell carcinoma (HNSCC) is one of the
most prevalent cancer worldwide with more than 600,000 cases
are diagnosed every year [1]. Tobacco usage and alcohol
consumption have been known to be the strongest risk factors
for the development of this disease [2]. However, it is now being
recognized that human papillomavirus (HPV) can also play a role
in the development of a subset of head and neck cancers [3]. Most
of the HNSCC are diagnosed in advanced stages and the outcome
of these patients is often poor [4]. Cisplatin is one of the commonly
used chemotherapeutic agents for the treatment of head and neck
cancers [5]. Cisplatin is an inorganic platinum agent, which can
bind to DNA, inducing intrastrand and interstrand DNA cross-
links, as well as DNA-protein cross-links. These cross-links result in
apoptosis and cell-growth inhibition [6]. However, many patients
develop resistance to cisplatin treatment leading to the treatment
failure [7]. Therefore, there is a need to develop novel therapeutic
strategies that are more effective and have fewer side effects than
currently used treatment regimens.
The signal transducers and activators of transcription (STATs)
are a family of signaling proteins that are activated by cytokines
and growth factors [8]. To date, 7 members of the STAT family
have been identified in mammals. In normal cells, STAT proteins
get transiently activated by phosphorylation and play a role in
cytokine and growth factor-mediated responses like cell growth,
survival and inflammation [9,10,11]. However, it has been
observed in numerous studies that STAT3 is constitutively active
in a variety of human solid tumors including lung cancer [12],
prostate cancer [13], breast cancer [14] and in more than 95% of
head and neck cancers [10]. Dysregulation and constitutive
activation of STAT3 stimulates cancer cell growth and contributes
to tumor development and progression by upregulation of STAT3
target genes including Bcl-2, c-myc, cyclin D1 and VEGF, which
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can enhance cell survival, proliferation and promote angiogenesis
[15,16,17]. Increased STAT3 expression has been linked to poor
prognosis in patients with gastric, colorectal cancers, cervical
squamous cell carcinoma and gliomas [18,19,20]. In addition,
STAT3 overexpression and signaling have been found to be
associated with cisplatin resistance in HNSCC [21,22]. Therefore,
intense efforts have focused on targeting STAT3 signaling using
novel therapeutic approaches which could induce apoptosis and
sensitize tumors to chemotherapy [23].
Recently, a novel class of diarylidenylpiperidone (DAP)
compounds has been synthesized by incorporating a piperidone
ring in the beta-diketone backbone structure of curcumin [24].
These compounds showed substantially higher anti-cancer activity
than curcumin in an ovarian cancer model [25]. It was also found
that these compounds inhibited the activation of STAT3. The aim
of this study was to evaluate the efficacy of one of the
diarylidenylpiperidone (DAP) compound, H-4073 either as a
single agent or in combination with cisplatin, both in vitro and in
vivo. We show that H-4073, as a single agent, was effective in
inhibiting tumor cell proliferation and inducing apoptosis.
Furthermore, H-4073 mediated inhibition of STAT3, focal
adhesion kinase (FAK), Akt and vascular endothelial cell growth
factor (VEGF) signaling pathways and was able to sensitize tumor
cells to the effects of cisplatin, resulting in inhibition of migration
and apoptosis in vitro as well as reduction in tumor volume in vivo.
Our data support the therapeutic use of H-4073 in combination
with cisplatin in the treatment of head and neck cancer.
Materials and Methods
Ethics Statement
All animal work was approved by the Ohio State University
IACUC Animal ethic committee and conducted according to their
guidelines (Animal Welfare Assurance Number A3261-01).
Cell Lines and Reagents
UM-SCC-74A, UM-SCC-1, UM-SCC-74B, UM-SCC-38 and
UM-SCC-47 were obtained from the laboratory of Dr. Thomas E.
Carey at the University of Michigan [26]. CAL27 was obtained
from ATCC (Manassas, VA). Cisplatin resistant cell line (CAL27-
CisR) was generated from its parental CAL27 cell line (ATCC) as
previously described [27]. The identity of all cell lines was
authenticated by STR genotyping (AmpFlSTR Identifiler PCR
Amplification Kit, Applied Biosystems, Carlsbad, CA). All the
head and neck cancer cell lines were cultured in Dulbecco’s
modified Eagle medium (DMEM, Invitrogen, Carlsbad, CA), 10%
fetal bovine serum, 1% penicillin/streptomycin and 1% non-
essential amino acids (Invitrogen). H-4073 was synthesized as
described previously [24]. The stock compound was freshly
dissolved in DMSO for in vitro work. For in vivo work, H-4073
was mixed with animal feed (50 ppm dose by Harlan Tekland).
Antibodies against pSTAT3 (Tyr705), pAkt (Ser473), pp38
(Thr180/Tyr182), pERK1/2 (Thr202/Tyr204) and GAPDH
were obtained from Cell Signaling Technology (Danvers, MA)
and pFAK (Tyr397) antibody was from Abcam (Cambridge, MA).
CD31 antibody was from Dianova (Hamburg, Germany) and p21
antibody was obtained from Calbiochem (EMD Millipore, Bill-
erica, MA).
Cellular Uptake
To determine the uptake of H-4073 by HNSCC cells in vitro,
UM-SCC-74A cells were grown in 10-cm dishes and treated
with10 mM of H-4073 or 100 mM curcumin. After 1 hour of
incubation, the cells were trypsinized, counted, and washed with
PBS. The cell pellet was allowed to dry, resuspended in methanol
and sonicated for 15 min. The sonicate was centrifuged at
10000 rpm for 5 minutes at 4uC. The supernatant was diluted
with an equal volume of methanol and measured with a UV/Vis
spectrophotometer (l=328 nm, e=25000 M21 cm21).
Cell Proliferation Assay
The sensitivity of cells to cisplatin and H-4073 was measured
using the MTT-based colorimetric cell proliferation kit (Roche
Applied Science, Mannheim, Germany) [27]. Briefly, 5000 cells/
well were plated in a 96 well plate. The next day, cells were treated
with different concentrations of H-4073, cisplatin, or a combina-
tion of both. After 72 hours, 10 ml/well of MTT solution was
added to each well and further incubated for 4 hours at 37uC. The
formazan crystals formed in the wells were solubilized by adding
solubilization solution and incubating the plates at 37uC overnight.
The plates were read at 590 nm on a Spectramax 190 plate reader
(Molecular Devices Inc., Sunnyvale CA). The percentage cell
growth inhibition for each treatment group was calculated by
adjusting the untreated control group to 100%. Data were
analyzed using GraphPad Prism software (GraphPad Sofware,
Inc., San Diego, CA) and the dose response curves were used to
calculate the concentration of H-4073 or cisplatin resulting in 50%
inhibition of cell proliferation (IC50) using a four parametric
logistical model. All experiments were repeated at least 3 times.
For drug combination studies, the synergistic effect was assessed
by the combination index (CI), according to the method of Chou
and Talalay wherein synergism is defined as CI,1, while
antagonism is CI.1, and an additive effect is considered as
CI= 1 [28]. The CI values were calculated using CompuSyn
software (ComboSyn, Inc., Paramus, NJ).
Colony formation assay
Tumor cells were plated in 6 cm dishes and treated with
cisplatin, H-4073 or a combination of both. After 48 hours of
treatment, 46103 viable cells from each group were plated in 6 cm
dishes and cultured for additional 10 days. The colonies were fixed
with methanol and stained with crystal violet. Photomicrographs
were taken and the number of colonies was counted by Alpha
Innotech imaging software (San Leandro, CA).
Apoptosis Assay
Cells were plated in 6-cm dishes and treated for 24 hours. Cell
culture supernatant and cells were collected 48 hours after
treatment. Cells were stained with Annexin V 488 (Life
Technologies, Grand Island, NY) and propidium iodide (Sigma,
St. Louis, MO) and analyzed by flow cytometry [27].
Immunoblotting
Cell lysates were run on Novex Bis-Tris gel (Invitrogen) under
reducing conditions, blotted onto PVDF membranes (GE
Healthcare Life Sciences/Amersham, Piscataway, NJ), probed
with primary antibodies, then rinsed and incubated with sheep
anti-mouse or donkey anti-rabbit conjugated with horseradish
peroxidase (GE Healthcare). The membranes were visualized
using the ECL Plus Kit (GE Healthcare).
Migration Assay
The effect on cell migration upon treatment was measured using
the xCELLigence RTCA DP Instrument (Roche Applied Science,
Mannheim, Germany) [29]. Briefly, cells were grown in serum-
free medium for 24 hours. The bottom chamber of the CIM-plate
16 was filled with 160 ml of complete medium. The bottom and
H-4073 Reverses Chemoresistance in HNSCC
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top chambers were snapped together. Serum-free medium was
placed in the top chamber and incubated for 1 hour in the CO2
incubator at 37uC. Cells were trypsinized, pelleted and resus-
pended so that 80,000 cells were added to each well of the top
chamber in serum free medium containing cisplatin, H-4073 or a
combination of both. The CIM-Plate 16 was placed in the RTCA
DP station and migration was monitored for 24 hours.
In vivo Studies
For anti-tumor efficacy studies, nude athymic mice bearing
tumor xenografts were used. All animal experiments were
performed under the guidelines of The Ohio State University
Committee for Use and Care of Animals. Tumor cells (16106)
were mixed with 100 ml of Matrigel and injected subcutaneously in
the flank area of the mice [30]. After 8 days, mice were stratified
into different groups (n = 5), so that the mean tumor volume in
each group was comparable. Animals were treated with H-4073
by mixing it with feed (50 ppm dose, Harlan Teklad) starting at
day 8. Animals were treated with cisplatin (5 mg/kg) at days 8, 11,
14, 17, 21, 24, and 28 via intraperitoneal injections. Tumor
volume measurements [volume (mm3) =L6W2/2 (length L, mm;
width W, mm)] began on day 6 and continued twice a week until
the end of the study. After 30 days, primary tumors were carefully
removed, photographed, and analyzed for pSTAT3, TUNEL-
positive cells and tumor angiogenesis.
Immunohistochemistry
The xenograft tumor tissues were fixed in 4% paraformalde-
hyde overnight and paraffin embedded. Tissue sections were
deparffinized, pretreated with antigen retrieval buffer (EDTA,
pH 8.0; pSTAT3) (Citrate, pH 6.0; CD31) [27]. Endogenous
peroxidase and non-specific binding sites were blocked and the
Figure 1. H-4073 inhibits STAT3 activation and head and neck cancer cell proliferation in a dose dependent manner. A: HNSCC cell
lines were treated with different concentrations of cisplatin (CDDP) and cell proliferation was assessed by MTT assay. B: Chemical structures of
curcumin and H-4073. C: UM-SCC-74A cells were cultured in 10-cm culture dishes and treated with curcumin or H-4073 for 1 hour. Cellular uptake of
curcumin and H-4073 was measured with a UV/Vis spectrophotometer. D: HNSCC cell lines were treated with different concentrations of H-4073 and
cell proliferation was assessed by MTT assay. E: UM-SCC-74A cells were treated with different concentrations of H-4073 for 2 hours. STAT3, FAK, Akt
and p38 phosphorylation was examined by Western blotting and equal protein loading was verified by stripping the blots and reprobing with
GAPDH antibody.
doi:10.1371/journal.pone.0093208.g001
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sections were incubated with pSTAT3 (Tyr 705) or CD31. The
primary antibody binding was detected using biotinylated goat
anti-rabbit IgG (Vector Laboratories, Burlingame, CA) or
biotinylated goat anti-rat IgG (BD Biosciences, San Jose, CA).
The slides were then incubated with avidin-biotin complex (Vector
Laboratories). The reaction sites were visualized using 3,39-
diaminobenzidine (DAB; Sigma Aldrich, St. Louis, MO). The
sections were counterstained with hematoxylin, dehydrated and
mounted with Permount.
The ApopTag Peroxidase In Situ Apoptosis Detection Kit
(EMD Millipore, Billerica, MA) was used to detect apoptotic cells
by terminal deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) staining in the xenograft tumor sections according to the
manufacturer’s protocol. Briefly, sections were deparaffinized,
rehydrated and incubated with Proteinase K for 15 minutes at
room temperature and then washed. The endogenous peroxidase
activity was quenched and after washing the sections were
incubated with working concentration of terminal deoxynucleoti-
dyl transferase (TdT) at 37uC for 1 hour. The sections were then
washed and incubated with anti-digoxigenin conjugate (peroxi-
dase) at room temperature. The signal was visualized with DAB as
chromogen.
Statistical Analysis
Data from all the experiments are expressed as mean 6 SEM
from a minimum of 3 independent experiments. The statistical
significance of the results was evaluated by two-way analysis of
variance or Student’s t test (wherever applicable) and a p value of
,0.05 was considered significant. IC50 values for H-4073 and
cisplatin for tumor cell proliferation inhibition was calculated using
GraphPad Prism software (GraphPad Sofware, Inc., San Diego,
CA) and combination index (CI) was calculated using CompuSyn
software (ComboSyn, Inc., Paramus, NJ).
Results
H-4073 is a potent inhibitor of HNSCC proliferation
The growth inhibitory effects of cisplatin in a panel of HNSCC
cell lines were evaluated using MTT assay. As shown in Fig. 1A,
cisplatin treatment inhibited the growth of HNSCC cell lines in a
dose dependent manner. We selected two cell lines (CAL27-CisR
and UM-SCC-74A) that were most resistant to cisplatin for further
experiments. UM-SCC-74A is squamous cell carcinoma cell line
derived from a base of the tongue tumor. This cell line was picked
to mimic natural or inherent cisplatin resistance. CAL27-CisR was
selected by growing the parental tongue squamous cell carcinoma
cell line (CAL27) in increasing concentrations of cisplatin over an
extended period of time [27]. This cell line was generated to
mimic acquired cisplatin resistant phenotype. Curcumin has been
extensive studied for its STAT3-inhibitory properties and anti-
tumor activity [31]. However, due to its poor bioavailability and
rapid metabolism, curcumin has not transitioned to clinic.
Figure 2. Synergistic anti-proliferative effects of H-4073 and cisplatin in head and neck cancer cells. A and C: UM-SCC-74A (A) or CAL27-
CisR (C) cells were treated with H-4073 or cisplatin (CDDP) alone or in combination at 0.25, 0.5, 1, 1.5 and 2 times their respective IC50 doses and cell
proliferation was assessed by MTT assay. Results were analyzed according to Chou-Talalay method and the combination index (CI) values calculated
by CompuSyn software. B and D: Bar diagrams showing cell proliferation results for UM-SCC-74A (B) and CAL27-CisR (D) at IC50 doses of H-4073 and
cisplatin (CDDP). *, represents a significant difference (p,0.05) as compared to no treatment group and **, represents a significant difference
(p,0.05) as compared to single treatment groups.
doi:10.1371/journal.pone.0093208.g002
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Therefore, we have developed a synthetic analog of curcumin, H-
4073 (Fig. 1B). In our study, H-4073 (10 mM) demonstrated .5-
fold higher cellular uptake in a head and neck cancer cell line
(UM-SCC-74A) as compared to curcumin (100 mM, Fig. 1 C). H-
4073 was highly effective in inhibiting cell proliferation of all
HNSCC cell lines that were tested, irrespective of their p53 status
or human papillomavirus status (HPV, Figure 1D). In our
mechanistic study, we observed a marked inhibition of STAT3,
FAK and Akt phosphorylation by H-4073 treatment in a
concentration-dependent manner (Fig. 1E). In addition, H-4073
treatment also induced the activation of p38 MAPK, a stress
activated kinase that is known to mediate cell death.
H-4073 synergistically enhanced the anti-tumor efficacy
of cisplatin in HNSCC cells
We next examined if H-4073 treatment could reverse cisplatin
resistance in head and neck cancer cells and enhance its anti-
tumor efficacy in a synergistic manner. We selected two cisplatin-
resistant cell lines, UM-SCC-74A (naturally cisplatin resistant) and
CAL27-Cis-R (generated in our laboratory) for all our studies. The
anti-proliferative effect of H-4073 and cisplatin (CDDP) combi-
nation treatment was measured by calculating the combination
index (CI) according to Chou-Talalay method [28] using a fixed
dose ratio. Both H-4073 and CDDP were added to the tumor cell
cultures at 0.256, 0.56, 16, 1.56 and 26 their respective IC50
doses. Cell proliferation in both the cell lines were markedly
decreased following combination treatment at the multiple paired
concentrations as compared to treatment with either of single
agents alone (Fig. 2). Combination index (CI) for different effective
doses (ED) was calculated using CompuSyn software. CI values for
UM-SCC-74A cells at ED50, ED75 and ED90 were 0.550, 0.537
and 0.244 respectively. The CI values for CAL27-CisR cells were
0.628, 0.606 and 0.507 at ED50, ED75 and ED90, respectively.
These results suggest that H-4073 and cisplatin combination
treatment was highly effective in inhibiting tumor cell proliferation
in a synergistic manner in both the cisplatin resistant cell lines.
We next investigated the effect of H-4073 alone or in
combination with cisplatin on tumor cell colony formation. As
observed with cell proliferation assay, a combination treatment
with H-4073 and cisplatin at their respective IC50 doses inhibited
tumor cell colony formation in a synergistic manner (93% in UM-
SCC-74A and 92% in CAL27-CisR cells) (Fig. 3A–C).
H-4073 inhibited cell migration and enhanced tumor cell
apoptosis
We next examined the effect of H-4073 and cisplatin
combination treatment on tumor cell motility by scratch assay.
H-4073 and cisplatin treatment alone showed 48% and 44%
inhibition of UM-SCC-74A cell motility and 46% and 42%
inhibition of CAL27-CisR cell motility, respectively (Fig. 4A–B).
H-4073 when combined with cisplatin showed significantly higher
inhibition of UM-SCC-74A and CAL27-CisR cell motility (85%
and 82%), respectively. In next set of experiments, we examined if
H-4073-mediated anti-tumor effects are mediated by apoptosis.
Indeed, H-4073 in combination treatment with cisplatin showed
significantly higher tumor cell apoptosis (Annexin V staining,
Fig. 4C) as compared to untreated cells or H-4073 and cisplatin-
treated cells alone. In addition, combination treatment signifi-
cantly inhibited STAT3 activation and markedly increased the
levels of activated caspase 3 and p21 (Fig. 4D).
H-4073 significantly enhanced the therapeutic efficacy of
cisplatin in cisplatin resistant head and neck cancers
Our in vitro data suggested that H-4073 significantly reversed
cisplatin resistance in head and neck cancer cells. We further
validated our in vitro results by using an athymic nude mouse
xenograft model. In the first set of experiments, we used a
naturally resistant head and neck cancer cell line (UM-SCC-74A).
H-4073 (50 ppm) and cisplatin (5 mg/kg) treatment alone showed
33% and 39% tumor growth inhibition at day 30, respectively
(Fig. 5A–B). H-4073 in combination with cisplatin showed
significantly higher tumor growth inhibition as compared to
untreated group (84%) or single agent alone (Fig. 5A–B). In
Figure 3. H-4073 markedly reduces tumor cell colony forma-
tion. CAL27-CisR (A–B) or UM-SCC-74a (C) cells were treated with H-
4073 or cisplatin (CDDP) alone or in combination for 48 hours. Four
thousand viable cells from each group were cultured for additional 10
days in 6-cm plates. Each assay was photographed and the number of
colonies analyzed. *, represents a significant difference (p,0.05) as
compared to no treatment group and **, represents a significant
difference (p,0.05) as compared to single treatment groups.
doi:10.1371/journal.pone.0093208.g003
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addition, the combination treatment was very well tolerated, and it
did not cause any animal toxicity or induce significant decrease in
body weight.
In the second set of experiments, we used cisplatin-resistant cell
line (CAL27-CisR, IC50 28 mmol/L) and its parental cisplatin-
sensitive cell line (CAL27, IC50 3 mmol/L). As we have previously
demonstrated [27], cisplatin treatment (5 mg/kg) of animals
bearing CAL27-CisR tumors did not significantly affect tumor
growth (9%) at day 30, whereas cisplatin treatment of its parental
cells (CAL27) markedly decreased tumor growth (45%). H-4073
treatment in CAL27-CisR cells was significantly more effective in
reducing tumor burden (32%). H-4073 and cisplatin combination
treatment was most effective in inhibiting tumor growth of
CAL27-CisR tumors (77%, Fig. 5C).
H-4073 and cisplatin combination treatment significantly
inhibited STAT3 phosphorylation in vivo and enhanced
tumor cell apoptosis
In our in vitro study, we have observed that H-4073 is a potent
inhibitor of STAT3 phosphorylation. We next examined if H-
4073 treatment inhibited SAT3 phosphorylation in vivo. UM-SCC-
74A tumors from mouse xenograft model were stained with
pSTAT3 antibody. H-4073 and cisplatin treatment significantly
inhibited STAT3 phosphorylation (43% and 30%, respectively).
H-4073 and cisplatin combination treatment was most effective in
inhibiting STAT3 phosphorylation (94%) (Fig. 6A–B). Similarly,
H-4073 and cisplatin combination treatment was most effective in
inducing apoptosis in tumor cells (Fig. 6C–D).
H-4073 inhibited tumor angiogenesis by downregulating
VEGF secretion from tumor cells
A number of studies have shown that STAT3 is a key regulator
of angiogenesis [16,32]. We next examined if H-4073 and cisplatin
combination treatment affected tumor angiogenesis. H-4073 and
cisplatin treatment alone showed 24% and 31% inhibition of
tumor angiogenesis in UM-SCC-74A (Fig. 7A–B), whereas H-
4073 and cisplatin combination treatment showed 62% inhibition
of tumor angiogenesis. We next examined if H-4073 inhibited
tumor angiogenesis by blocking VEGF production by tumor cells.
UM-SCC-74A cells were treated with H-4073 and VEGF levels in
culture supernatants were measured by ELISA. Untreated UM-
SCC-74A cells produced high levels of VEGF (1121 pg/ml/106
cells, Fig. 7C). H-4073 and cisplatin treatment alone showed 36%
and 55% inhibition of VEGF levels. H-4073 and cisplatin
combination treatment significantly inhibited VEGF production
(83%). In the next set of experiments, we examined if H-4073
could directly affect angiogenic function of endothelial cells by
inhibiting VEGF signaling. Our results from this study demon-
strate that H-4073 markedly inhibit VEGF-mediated ERK1/2
and Akt phosphorylation (Fig. 7D). In addition to inhibiting the
pro-survival signaling molecules (ERK1/2 and Akt) H-4073 also
activated p38 MAPK (a pro-apoptotic molecule) in a dose
dependent manner (Fig. 7D).
Figure 4. H-4073 and cisplatin significantly inhibits tumor cell migration and enhances apoptosis. A–B: Tumor cell motility was
examined by scratch assay. Each assay was photographed and distances between the migrating cell edges were quantified and percentage cell
migration was calculated. *, represents a significant difference (p,0.05) as compared to no treatment group and **, represents a significant
difference (p,0.05) as compared to single treatment groups. C–D: UM-SCC-74A cells were treated with H-4073 or cisplatin (CDDP) alone or in
combination. After 24 hours, cells were either stained with Annexin V and analyzed by flow cytometry or Western blotted for pSTAT3, p21 or cleaved
caspase 3. Equal protein loading was verified by stripping the blots and reprobing with GAPDH antibody.
doi:10.1371/journal.pone.0093208.g004
H-4073 Reverses Chemoresistance in HNSCC
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Discussion
Patients with head and neck cancer encompass a heterogeneous
group and even with advancement in treatment options, the
overall survival rate for patients with advanced disease has not
changed substantially over recent decades [33]. Surgery followed
by adjuvant radiotherapy has long been used in the management
of patients with HNSCC [34]. More recently, platinum-based
Figure 5. H-4073 and cisplatin combination treatment significantly inhibits tumor growth. Animals bearing UM-SCC-74A, CAL27 and
CAL27-CisR were treated with H-4073 (50 ppm) or cisplatin (CDDP, 5 mg/kg) alone or in combination. A: Representative photomicrographs of UM-
SCC-74A tumors from untreated, cisplatin (CDDP), H-4073, or CDDP and H-4073-treated groups. B: Tumor growth curves for UM-SCC-74A tumors
treated with cisplatin (CDDP), H-4073, or CDDP and H-4073. C: Tumor growth curves for CAL27 and CAL27-CisR tumors treated with cisplatin (CDDP),
H-4073, or CDDP and H-4073. *, represents a significant difference (p,0.05) as compared to no treatment group and **, represents a significant
difference (p,0.05) as compared to single treatment groups.
doi:10.1371/journal.pone.0093208.g005
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regimens are being integrated into the treatment options [35].
However, many of the patients develop resistance to cisplatin, one
of the most widely used platinum agent, leading to treatment
failure [21,36]. Therefore, there is an urgent need to develop novel
therapeutic agents that specifically targets pro-survival pathways.
Recent studies have shown that STAT3 is constitutively activated
in tumor cells and is overexpressed in cisplatin-resistant cell lines
[21,37]. STAT3 is involved in the suppression of apoptosis in
cisplatin resistant cell lines by upregulating survival genes like Bcl-
xL, Bcl-2 and survivin [38,39]. Therefore, we hypothesized that
targeting STAT3 could reverse the resistant phenotype in tumor
cells, thereby enhancing the anti-tumor effects of cisplatin
treatment in HNSCC.
To test this hypothesis, we have carried out combination
treatment studies in vitro and in vivo using athymic nude xenograft
model. In this study, we selected a novel analog of curcumin (H-
4073) because curcumin has been shown to be a potent inhibitor
of STAT3 and demonstrate anti-tumor activity in various cancers
including head and neck cancer. However, its instability in vitro
and poor bioavailability has limited its clinical application. We
therefore developed a novel DAP analog of curcumin (H-4073)
[24]. In our bioabsorption studies, H-4073 demonstrated signif-
icantly higher (.5 fold) cellular uptake in head and neck cancer
cells as compared to curcumin. We did note that the level of
bioabsorption of H-4073 varied between different cell lines. We
think that this difference could be due to differential expression of
multiple drug influx and efflux transporters in these cell lines [40].
We then used various HNSCC cell lines (HPV positive, HPV
negative, wild-type p53 or mutant p53) to check the ability of H-
4073 to inhibit growth in vitro. We found that H-4073 inhibited the
growth of cell lines irrespective of p53 or HPV status in a dose
dependent manner. If this finding could be broadly translated into
clinical efficacy in heterogeneous HNSCC tumors (50–80%
mutant p53, 60–80% of oropharynx tumors are HPV positive),
H-4073 could represent a promising new agent for targeted
therapy in HNSCC. Interestingly, majority of the head and neck
cancer patients with HPV positive tumors respond very well to
traditional chemotherapy with cisplatin and demonstrate signifi-
cantly favorable clinical outcome [33,41]. It is the patients with
HPV negative tumors that show markedly poor clinical outcome
and often develop resistance to chemotherapy. Therefore, this
non-HPV associated patient population could tremendously
benefit from the addition of targeted therapies to currently used
treatment regimens. In this study, we have used 2 HPV-negative
HNSCC cell lines (UM-SCC-74A and CAL27-CisR). UM-SCC-
74A cell line is derived from a head and neck cancer patient with
Figure 6. H-4073 and cisplatin treatment significantly inhibits STAT3 phosphorylation and markedly increases tumor cell
apoptosis, in vivo. A–D: Paraffin-embedded UM-SCC-74A tumor samples were stained for pSTAT3 (Y705) and apoptotic cells (Apop Tag kit). A:
Representative photomicrographs of tumor samples stained for pSTAT3 from untreated, cisplatin (CDDP) or H-4073 alone or combination groups. B:
pSTAT3 positive cells were quantified in 5 high power fields (4006) of each tumor samples and percentage of positive cells calculated. C:
Representative photomicrographs of tumor samples stained for apoptotic cells from untreated, cisplatin (CDDP) or H-4073 alone or combination
groups. D: TUNEL-positive cells were quantified in 5 high power fields (4006) of each tumor samples and percentage of positive cells calculated. *,
represents a significant difference (p,0.05) as compared to no treatment group and **, represents a significant difference (p,0.05) as compared to
single treatment groups.
doi:10.1371/journal.pone.0093208.g006
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base of tongue tumor and is highly resistant to both chemotherapy
and radiation treatment [42,43]. In addition, we generated a
cisplatin-resistant cell line (CAL27-CisR, IC50 28 mM) in our
laboratory by culturing a cisplatin sensitive tongue SCC cell line
CAL27 (IC50 3 mM) in increasing doses of cisplatin over a period
of time [27].
H-4073 treatment was very effective in inhibiting tumor cell
proliferation, colony formation and cell migration. In addition, H-
4073 pretreatment significantly reversed cisplatin resistance in
both naturally resistant head and neck cancer cell line (UM-SCC-
74A) as well as in cell line with acquired cisplatin resistance
(CAL27-CisR). Combination index analysis by Chou-Talalay
method [28] demonstrated that H-4073 and cisplatin combination
treatment is highly effective and synergistic in mediating anti-
tumor effects. These potent anti-tumor effects of H-4073 could be
due to its inhibitory effects on a number of key signaling pathways
including STAT, FAK, Akt and VEGF. STAT3 activation has
been demonstrated in HNSCC tumor samples obtained from
patients that developed resistance to cetuximab or cisplatin
treatment [21,44]. Huang et al have also demonstrated that
inhibition of STAT3 signaling in cisplatin-resistant gastric cancer
cells by using siRNA significantly reversed cisplatin resistance [45].
We also observed a marked decrease in Akt phosphorylation in H-
4073 treated cells. Akt inhibition by H-4073 could also be
contributing to reversal of chemoresistance in head and neck
cancer cells as Akt has been shown to mediate chemoresistance in
a number cancer types [46,47]. A number of studies have
demonstrated the role of FAK in cell survival particularly
anchorage dependent survival [48,49]. Recent studies have also
highlighted the role of FAK in cell migration [50]. We observed
that H-4073 treatment markedly inhibited FAK phosphorylation.
This could be a direct effect of H-4073 on FAK phosphorylation
or indirectly mediated through STAT3 as we have previously
shown that STAT3 can regulate FAK activation in head and neck
cancer cells [29].
To further determine if the observed in vitro synergy between H-
4073 and cisplatin extends to the in vivo setting, we used a nude
mouse xenograft model to study the effect of combination
treatment on tumor growth and tumor angiogenesis. Indeed
combination treatment of H-4073 (50 ppm) and cisplatin (5 mg/
kg) induced significant reduction in tumor burden. This marked
inhibition of tumor growth by combination treatment could be
because of H-4073-mediated inhibition of STAT3, Akt and FAK
signaling pathways as well as reduction in the formation of new
blood vessels by reducing VEGF production and inhibiting VEGF
signaling. H-4073 and cisplatin combination treatment was very
well tolerated in the animals. It did not cause any animal mortality
or induced any significant weight loss or induced any major
systemic toxicity such as dry scaly skin or respiratory distress that
has been reported in animals treated with chemotherapy
treatment with other small molecular weight inhibitors [51]. In
conclusion, we have shown that H-4073 significantly enhances the
anti-tumor effects of cisplatin treatment by inhibiting tumor
growth and tumor angiogenesis. Therefore, H-4073 with its low
Figure 7. H-4073 and cisplatin combination treatment significantly inhibits tumor angiogenesis. A: Representative photomicrographs of
tumor blood vessel staining for untreated, cisplatin (CDDP) or H-4073 alone or combination groups for UM-SCC-74A tumors. B: Microvessel density in
the tumor samples was calculated by counting 5 random fields (2006) and expressed as vessel density 6 SE. C: UM-SCC-74A cells were treated with
cisplatin or H-4073 alone or in combination. After 72 hours, culture supernatants were collected and assayed for VEGF levels. *, represents a
significant difference (p,0.05) as compared to no treatment group and **, represents a significant difference (p,0.05) as compared to single
treatment groups. D: Endothelial cells were treated with VEGF in the presence or absence of different concentrations of H-4073 for 30 minutes. ERK1/
2, Akt and p38 phosphorylation was examined by Western blotting and equal protein loading was verified by stripping the blots and reprobing with
GAPDH antibody.
doi:10.1371/journal.pone.0093208.g007
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toxicity and good bioavailability is a potentially novel candidate to
enhance the therapeutic efficacy of cisplatin treatment in head and
neck cancer patients.
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